Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Other: 2022-2024

Historic Receivables - Other for Apellis Pharmaceuticals (APLS) over the last 3 years, with Dec 2024 value amounting to $4.5 million.

  • Apellis Pharmaceuticals' Receivables - Other rose 31.79% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 31.79%. This contributed to the annual value of $4.5 million for FY2024, which is 48.17% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Receivables - Other stood at $4.5 million, which was up 48.17% from $3.1 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Receivables - Other peaked at $4.5 million during FY2024, and registered a low of $1.4 million during FY2022.
  • Moreover, its 3-year median value for Receivables - Other was $3.1 million (2023), whereas its average is $3.0 million.
  • Data for Apellis Pharmaceuticals' Receivables - Other shows a peak YoY soared of 111.79% (in 2023) over the last 5 years.
  • Apellis Pharmaceuticals' Receivables - Other (Yearly) stood at $1.4 million in 2022, then spiked by 111.79% to $3.1 million in 2023, then skyrocketed by 48.17% to $4.5 million in 2024.